Effects of oral or injectable semaglutide on Diabetes Therapy-Related Quality of Life scores in obese patients with type 2 diabetes: A single-center observational study.

Effects of oral or injectable semaglutide on Diabetes Therapy-Related Quality of Life scores in obese patients with type 2 diabetes: A single-center observational study. - An observational study of the effects of oral or injectable semaglutide on DTR-QOL scores.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057021

Enrollment

Registered

2025-02-18

Start date

2025-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Obese patients with type 2 diabetes aged 20 years or older who are planned to be treated with oral or injectable semaglutide 2)Patients who showed written consent form

Exclusion criteria

Exclusion criteria: 1)Patients who have contraindications for semaglutide 2)Patients who have previously received semaglutide treatment 3)Patients with a history of hypersensitivity to the components of semaglutide 4)Patients with type 1 diabetes or diabetes due to other causes 5)Pregnant women, breastfeeding women, and patients planning to become pregnant 6)Patients who require treatment due to serious complications such as diabetic ketoacidosis, diabetic coma or precoma, and severe infections and who are deemed inappropriate for participation in this study by a doctor 7)Patients with poorly controlled type 2 diabetes with HbA1c of 10.0% or higher 8)Patients undergoing treatment for malignant tumors 9)Patients with obvious dementia 10)Patients who are deemed inappropriate for participation in this study by the principal investigator or co-investigator

Design outcomes

Primary

Measure	Time frame
The change in total score of the Diabetes Therapy-Related QOL questionnaire from baseline to week 12	—

Secondary

Measure	Time frame
1)The percentage change in total score of the Diabetes Therapy-Related QOL questionnaire from baseline to week 12 2)The change or percentage change in clinical variables from baseline to week 12 3)The relationship between the change in total score of the DTR-QOL questionnaire and clinical variables/characteristics of participants 4)The relationship between the change in each domain score of the DTR-QOL questionnaire and clinical variables/characteristics of participants 5)Nutrient and energy intake evaluated by the Brief-type self-administered Diet History Questionnaire (BDHQ)	—

Measure

Time frame

1)The percentage change in total score of the Diabetes Therapy-Related QOL questionnaire from baseline to week 12 2)The change or percentage change in clinical variables from baseline to week 12 3)The relationship between the change in total score of the DTR-QOL questionnaire and clinical variables/characteristics of participants 4)The relationship between the change in each domain score of the DTR-QOL questionnaire and clinical variables/characteristics of participants 5)Nutrient and energy intake evaluated by the Brief-type self-administered Diet History Questionnaire (BDHQ)

—

Countries

Japan

Contacts

Public ContactYasutaka Takeda

Kanazawa Medical University Department of Diabetology & Endocrinology

yktake5@kanazawa-med.ac.jp076-286-2211

Outcome results